KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. Co. has developed a proprietary portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema. Co.'s primary focus is on developing oral plasma kallikrein inhibitors for HAE. Co. has developed its candidate sebetralstat into clinical development as a potential oral, on-demand therapy for HAE attacks. Co.'s oral product candidate, KVD824 is also being developed for potential prophylactic treatment of HAE. The KALV stock yearly return is shown above.
The yearly return on the KALV stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KALV annual return calculation with any dividends reinvested as applicable (on ex-dates).
|